Abstract: A novel label-free sensitive detection method by employing a novel sensitive charge sensor is provided. Dissociation constant information is provided by a simple measurement of the dissociation of the target molecule form the target's receptor. The later process is affected by a novel system and its configuration as described herein. Basic objectives are to provide a drug discovery and characterization system that is an improvement over the current state of the art, low cost, highly sensitive, accurate, fast and easy to use. This invention involves both a physical system and a methodology.

Abstract: Included are methods of identifying compounds that mimic the interaction of Apoptin and APC1, e.g., binding of Apoptin to APC1, e.g., dissociation of APC1 from the APC/C, and compounds identified by the methods. Compounds that specifically mimic an interaction of Apoptin and APC1, e.g., cause dissociation of APC1 from the APC/C, are useful for promoting apoptosis (e.g., in cancer cells). Also included are methods of treating a subject having a disorder characterized by aberrant (e.g., decreased) apoptotic processes, by administering a compound that appropriately mimics an interaction of Apoptin and APC1.

Abstract: A method of growing semiconductor materials in the Indium, Aluminium, Gallium Nitride (InAlGaN) material system and to devices made therefrom, in particular optical devices in the ultraviolet to green region of the visible spectrum. Certain optical devices, for example Vertical Cavity Surface Emitting Lasers (VCSELs) require great precision in the thickness of certain semiconductor layers. One aspect of the present invention provides a gallium-rich group III nitride layer (200, 201) and an adjacent layer of AlxInyGa1-x-yN layer (202). The AlxInyGa1-x-yN layer (202) acts as a fabrication facilitation layer and is selected to provide a good lattice match and high refractive index contrast with the gallium-rich group III nitride layer (200, 201). The high refractive index contrast permits in-situ optical monitoring. The extra layer (202) can be used as an etch marker or etch stop layer in subsequent processing and may be used in a lift-off process.

Abstract: The present invention provides phosphorus-based oxazine compounds and the preparation method thereof. The phosphorus-based oxazine compounds of the present invention can provide better fire-resistant characteristics, while the preparation method for the phosphorus-based oxazine compound of the present invention can offer high yields and/or high purity phosphorus-based oxazine compounds.

Abstract: A mixing reactor for mixing efficiently streams of fluids of differing densities. In a preferred embodiment, one of the fluids is supercritical water, and the other is an aqueous salt solution. Thus, the reactor enables the production of metal oxide nanoparticles as a continuous process, without any risk of the reactor blocking due to the inefficient mixing inherent in existing reactor designs.

Abstract: Tumor Necrosis Factor Related Ligand (TRELL) polypeptides, a novel member of the tumor necrosis factor family (TNF) and compositions comprising them are disclosed.

Abstract: Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.

Abstract: Antagonists for modifying protein-protein interactions involving certain amino acid sequences within MMP-9 and/or ?1 integrins are described. Such antagonists inhibit angiogenesis, tumor growth and disease states. Example antagonists are polypeptide and non-polypeptide molecules, including the novel antibody Mab FM155 and the novel synthetic peptide FRIP-1. Methods for inhibiting angiogenesis and disease states by administering such antagonists are disclosed. Methods for identifying antagonists that modify protein-protein interactions involving certain amino acid sequences within MMP-9 and/or ?1 integrins are also described.

Abstract: The present invention features modified Mycobacterium tuberculosis strains which lack a functional lspA gene, and vaccine formulations comprising the same. In many embodiments, a modified Mycobacterium tuberculosis strain of the invention comprises deletion or inactivation of the lspA gene and/or one or more non-lspA genes that are involved in Mycobacterium tuberculosis inhibition of macrophage responses to IFN?. The present invention also features methods of using the modified Mycobacterium tuberculosis strains to treat or present Mycobacterium tuberculosis infection in mammals. In addition, the present invention features methods of using ?lspA strains to identify non-lspA genes or other cellular components that are involved in Mycobacterium tuberculosis proinflammatory stimulation of macrophages or inhibition of macrophage responses to IFN?.

Abstract: A waveguide structure is described wherein microwaves or radio-frequency waves can be guided in their propagation through channels whose cross-sections contain fractal patterns, with relevant dimensions much smaller than the wavelengths of the guided waves. A finite section of such waveguide can be used as an efficient delay line.

Abstract: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).

Abstract: The present invention provides polypeptides involved in cryptophycin biosynthesis and the nucleic acid molecules that encode such polypeptides. The nucleic acid molecules and polypeptides of the invention or variants thereof can be used in the methods of the invention to produce cryptophycins.

Abstract: Methods of increasing the cellular pool of A-CoA and thus driving the metabolic pathways in the direction of A-CoA containing metabolites by overexpressing rate limiting enzymes in A-CoA synthesis. Methods of increasing intracellular levels of CoA and A-CoA through genetic engineering of bacterial strains in conjunction with supplementation with precursor molecules.

Abstract: A remote control system capable of precise operations or treatments in which the visual recognition and operation portions are as close to each other as possible, including: a) an imaging device for taking an image of the object; b) a manipulation tool having at its tip an illuminator for casting a spot light onto the object; c) a driver for changing the position of the manipulation tool; d) an external display unit for displaying an image; e) an input unit for allowing an operator to specify a position corresponding to the display of the external display unit; f) a distance calculator for calculating the distance between the position specified through the input unit and the position of the spot light cast from the illuminator onto the object; and g) a controller for controlling, based on the aforementioned distance, the driver so as to bring the tip of the manipulation tool closer to the specified position.

Abstract: The invention provides a circuit system for driving a high-intensity discharging lamp, comprising a boosting circuit, an ignition coil circuit and a clamp circuit. The boosting circuit includes a first transformer and a first switch, in which the primary of the first transformer receives an input power, the secondary of the first transformer produces a boosting DC voltage, and the first switch is connected to the first transformer to control turning-on and turning-off of the first transformer. The ignition coil circuit is connected to the boosting circuit for converting the boosting DC voltage into a switching AC voltage to drive a load. The clamp circuit is connected to the boosting circuit and the ignition coil circuit for directing energy, reflected from the secondary of the first transformer to the primary of the first transformer, to the secondary of the first transformer as the first switch is turned off.

Abstract: An organic light emitting display includes a pixel unit including a plurality of pixels arranged at intersecting points of data lines, scan lines and light emitting control lines; a temperature sensor provided to measure a temperature of the pixel unit; a first analog/digital converter (first ADC) to convert information of the temperature measured in the temperature sensor into a first digital value; a controller to receive the first digital value outputted from the first ADC and outputting a control signal corresponding to the received first digital value; a sensing unit to extract a degradation level of an organic light emitting diode included in each of the pixels; a second analog/digital converter (second ADC) to receive information of the degradation of the organic light emitting diode extracted from the sensing unit and a control signal outputted from the controller and generating a second digital value corresponding to the information of the degradation of the organic light emitting diode that is varie

Abstract: Disclosed are compounds that release nitric oxide, e.g., a compound of Formula (I) wherein R1-10, X, and n are as described herein, which are NSAID derivatives comprising a diazeniumdiolate moiety N2O2?. The compounds are chemopreventive agents with gastric-sparing, analgesic, cardioprotective, and/or anti-inflammatory properties. Also disclosed is a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier. Also disclosed is a method of preventing or treating cancer or treating inflammation or an inflammation-related condition in a mammal comprising administering an effective amount of a compound of the invention to the mammal.

Abstract: Disclosed are a system and a process for identifying P2P applications and specific P2P software as well from an original mixed packet trace based on behavioral-signatures. The behavioral-signature based system and process according to the invention is mainly to check whether the application has these specific periodic behaviors or not. The process of this invention comprises the steps of filtering out all irrelative packets; translating the filtered packet trace into discrete-time sequences; processing the sequences to obtain frequency-domain characteristics of original packet trace; and analyzing the frequency-domain characteristics and determining the identification.

Abstract: Disclosed is a clock-based data storage device, which includes a dual pulse generating device and a data starge device having two dynamic nodes for prior chargement/dischargement.